Mcl-1 downregulation enhances BCG treatment efficacy in bladder cancer by promoting macrophage polarization.

ABSTRACT:

Background

Bacillus Calmette-Guérin (BCG) is the primary method of postoperative perfusion treatment for bladder cancer. The myeloid cell leukemia gene-1 (Mcl-1) is closely associated with the development of malignant tumors. Previous research by our group has demonstrated that downregulating Mcl-1 using shRNA can enhance the efficacy of BCG treatment in bladder cancer. This study aims to investigate the impact of Mcl-1 downregulation in combination with BCG treatment on bladder cancer, macrophage polarization, and the underlying mechanism of action, with the goal of reducing recurrence and metastasis in bladder cancer.

Methods

The GSE190529 dataset was analyzed to identify differential genes for enrichment analysis. The WGCNA algorithm was then employed to pinpoint gene mod

SUBMITTER: Tan C 

PROVIDER: S-EPMC11830210 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature